Universal pathogen-reduced plasma in elective open-heart surgery and liver resection

Clinical Medicine and Research

Volumn 4, Issue 3, 2006, Pages 209-217

  Solheim, Bjarte G ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

ABO blood group system; Blood transfusion; Cost effectiveness; Liver resection; Open heart surgery; Pathogen reduction; Universal ABO independent plasma

Indexed keywords

BLOOD GROUP A ANTIBODY; BLOOD GROUP B ANTIBODY; DETERGENT; SOLVENT;

BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION REACTION; CLINICAL STUDY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; ELECTIVE SURGERY; HEMOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER RESECTION; OPEN HEART SURGERY; PATIENT MONITORING; PATIENT SAFETY; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDY; PROTEIN ANALYSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK FACTOR; TRANSFUSION RELATED ACUTE LUNG INJURY;

ABO BLOOD-GROUP SYSTEM; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; HUMANS; ISOANTIBODIES; LIVER; LUNG; PLASMA; SAFETY;

EID: 33749361738     PISSN: 15394182     EISSN: None     Source Type: Journal    
DOI: 10.3121/cmr.4.3.209     Document Type: Review

References (40)

1. Stainsby D. Haemovigilance in the United Kingdom and Europe. Hematol J 2004;5:S175-S178.
2. Henderson RA, Finder L. Acute transfusion reactions. N Z Med J 1990;103:509-511.
3. College of American Pathologist. Transfusion medicine survey (J-A). 2005.
4. Spalter SH, Kaveri SV, Bonnin E, Mani JC, Cartron JP, Kazatchkine MD. Normal human serum contains natural antibodies reactive with autologous ABO blood group antigens. Blood 1999;93:4418-4424.
5. McManigal S, Sims KL. Intravascular hemolysis secondary to ABO incompatible platelet products. An underrecognized transfusion reaction. Am J Clin Pathol 1999;111:202-206.
6. Baele PL, De Bruyere M, Deneys V, Dupont E, Flament J, Lambermont M, Latinne D, Steensens L, van Camp B, Waterloos H. Bedside transfusion errors. A prospective survey by the Belgium SAnGUIS Group. Vox Sang 1994;66:117-121.
7. Fiesland O, Seghatchian J, Solheim BG. The Norwegian Plasma Fractionation Project-a 12 year clinical and economic success story. Transfus Apher Sci 2003;28:93-100.
8. HMSO: Dried human plasma. HMSO, London; 1973.
9. Chapanduka ZC, Fernandes-Costa FJ, Rochat C, Blyth DF. Comparative safety and efficacy of Bioplasma FDP versus single-donor fresh-dried plasma in cardiopulmonary bypass patients. S Afr Med J 2002;92:356-357.
10. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-831.
11. Biesert L, Suhartono H. Solvent/detergent treatment of human plasma-a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang 1998;74 (suppl 1):207-212.
12. Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U. Viral safety of solvent/detergent-treated plasma. Transfusion 2000;40:84-90.
13. Solheim BG, Hellstem P. Composition, efficacy, and safety of S/D-treated plasma. Transfusion 2003;43:1176-1178.
14. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, Seitz R, Heiden M. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med 2006;16:266-275.
15. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004;11:346-350.
16. Hellstern P, Haubelt H. Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 2002;107:S3-S8.
17. Beeck H, Hellstern P In vitro characterization of solvent/detergent- treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998;74(suppl 1):219-223.
18. Heger A, Romisch J, Svae TE. Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing. Transfus Apher Sci 2005;33:257-267.
19. Noddeland H, Tollofsrud S, Svennevig J, Bentsen G, Brosstad F, Solheim B. Universal solvent/detergent-treated fresh frozen plasma (Uniplas)-rationale and clinical properties. Thromb Res 2002;107:S33-S37.
20. Tollofsrud S, Noddeland H, Svennevig JL, Bentsen G, Mollnes TE, Solheim BG. Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med 2003;29:1736-1743.
21. Solheim BG, Granov DA, Juravlev VA, Krawczyk M, Kubishkin VA, Patutko UI, Raab R. Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang 2005;89:19-26.
22. Garred P, Mollnes TE, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988;27:329-335.
23. Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985;22:197-202.
24. Shanwell A, Ringden O, Wiechel B, Rumin S, Akerblom O. A study of the effect of ABO incompatible plasma in platelet concentrates transfused to bone marrow transplant recipients. Vox Sang 1991;60:23-27.
25. Mair B, Benson K. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets. Transfusion 1998;38:51-55.
26. Solheim BG, Bergan A, Brosstad F, Innes R, Svennevig JL. Fibrinolysis during liver transplant and use of solvent/detergent virus-inactivated plasma (ESDEP/Octaplas). Anesth Analg 2003;96:1230-1231.
27. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003;121:778-785.
28. Rock G, Clark B, Sutton D; CAG; CAAN. The Canadian apheresis registry. Transfus Apher Sci 2003;29:167-177.
29. Solheim BG, Seghatchian J. What is happening. Update on pathogen reduction technology for therapeutic plasma: An overview. Transfus Apheresis Sci 2006 (in press).
30. [No authors listed]. Transfusion of apheresis platelets and ABO groups. Vox Sang 2005;88:207-221.
31. Myhre BA, McRuer D. Human error-a significant cause of transfusion mortality. Transfusion 2000;40:879-885.
32. Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion 2000;40:1207-1213.
33. Krombach J, Kampe S, Gathof BS, Diefenbach C, Kasper SM. Human error: the persisting risk of blood transfusion: a report of five cases. Anesth Analg 2002;94:154-156.
34. Bux J. Transfusion-related acute lung injury (TRAL1): a serious adverse event of blood transfusion. Vox Sang 2005;89:1-10.
35. Sinnott P, Bodger S, Gupta A, Brophy M. Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Eur J Immunogenet 2004;31:271-274.
36. Sachs UJ, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 2005;45:1628-1631.
37. Solheim BG. Plasma-induced TRALI is avoided with solvent/detergent- treated plasma [abstract]. Transfusion Alternatives in Transfusion Medicine 2005;7(suppl):57. Abstract P16.
38. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 1999;39:479-487.
39. Jackson BR, AuBuchon JP, Birkmeyer JD. Update of cost-effectiveness analysis for solvent-detergent-treated plasma. JAMA 1999;282:329.
40. Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003;85:88-95.